JERUSALEM--(BUSINESS WIRE)--Sept. 12, 2005--Chiasma Inc., a developer of an innovative platform technology for oral delivery of macromolecule drugs, has announced the completion of a $6.2 million Series B financing round. Chiasma intends to use these funds to advance its lead therapeutic candidates through clinical trials.
The investment round was co-led by F-2 Ventures and the Ofer Hi-Tech Group, joined by the InnoMed Fund, which funded the entire Series A round, and by Yissum Ltd.
